SCHEMBL17440261

SCHEMBL17440261

CC(C)(C)N(C(=O)O)C1CCCC(C=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2695239 0.81
SCHEMBL2695237 0.81
SCHEMBL18244429 0.77 CNR2 (0.30)
SCHEMBL16822017 0.77 CNR2 (0.30)
SCHEMBL1061762 0.76 TRPM8 (0.35)
SCHEMBL1543231 0.76 TRPM8 (0.35)
SCHEMBL1543480 0.76 TRPM8 (0.35)
SCHEMBL1543478 0.76 TRPM8 (0.35)
SCHEMBL1543230 0.76 TRPM8 (0.35)
SCHEMBL527479 0.73 DPP4 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9908895-B2 Tricyclic fused thiophene derivatives as JAK inhibitors INCYTE CORPORATION (US) 2018-03-06 US disclosed
US-20160024109-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS INCYTE HOLDINGS CORPORATION 2016-01-28 US disclosed
US-20160015695-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2016-01-21 US disclosed